Differential Vascular and Non‐Vascular Binding Patterns of ACU193 and R‐Lecanemab in APP;hAPOE4 Mouse Brain Sections

Abstract

Background: Therapeutic anti‐amyloid‐beta (Aβ) monoclonal antibodies (mAbs), lecanemab (Leqembi) and donanemab (Kisunla), have received FDA approval for treatment of early‐stage Alzheimer's disease (AD).

The paper